Although Bcl6 deletion alone greatly improved the therapeutic efficacy, the combination of Bcl6 deletion and anti-CTLA4 or anti-PD1 did exhibit additional effects at delaying tumor growth (Figures 5C–E), indicating that Bcl6 can be a potential therapeutic target combined with ICB in cancer immunotherapy. The gene discussed is BCL6; the disease is cancer.